Therapie mit atypischen Neuroleptika aus gesundheitspolitischer Sicht: Versuch einer gesundheitsökonomischen Analyse

  • J. Fritze
Conference paper

Zusammenfassung

Die Gesundheitspolitik beschäftigt sich in aller Regel nicht mit medizinischen Detailfragen, sondern verweist auf die „Fachebene“. Das mag sich zunehmend ändern, und die Gründe für einen solchen Trend liegen im Zweifelsfall in der gesundheitsökonomischen Dimension. Dies ist auch der Grund, warum eine gesundheitspolitische Betrachtung der modernen, atypischen Neuroleptika gefordert wird. Der Grund liegt in den 5- bis lOfach höheren Tagesbehandlungskosten, und dies angesichts der sog. Kostenexplosion im Gesundheitswesen. Daraus ist bisher jedoch kein für diese Neuroleptika spezifisches, gesundheitspolitisches Problembewußtsein entwickelt worden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Davies LM, Drummond MF (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 162:38–42PubMedCrossRefGoogle Scholar
  2. 2.
    Essock SM, Hargreaves WA, Covell NH, Goethe J (1996) Clozapine’s effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 32:683–697PubMedGoogle Scholar
  3. 3.
    Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L (1996) Clozapine eligibility among state hospital patients. Schizophr Bull 22:15–25PubMedGoogle Scholar
  4. 4.
    Freeman HL (1997) Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies. Int Clin Psychopharmacol 12: S11–S17PubMedCrossRefGoogle Scholar
  5. 5.
    Hamilton SH, Revicki DA, Genduso LA, Besley CM (1998) Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18: 41–49PubMedCrossRefGoogle Scholar
  6. 6.
    Henke KD, Martin K, Behrens C (1997) Direkte und indirekte Kosten von Krankheiten in der Bundesrepublik Deutschland 1980 und 1990. Z f Gesundheitswiss 5:123–145Google Scholar
  7. 7.
    Kennedy BL, Schwab JJ (1997) Utilization of medical specialists by anxiety disorder patients. Psychosomatics 38:109–112PubMedCrossRefGoogle Scholar
  8. 8.
    Kissling W (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand Suppl 89:16–24CrossRefGoogle Scholar
  9. 9.
    Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997) Depression in the community: The first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12: 19–29PubMedCrossRefGoogle Scholar
  10. 10.
    Moller HJ, Boyer P, Fleurot O, Rein W (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacology 132:396–401PubMedCrossRefGoogle Scholar
  11. 11.
    Naber D (1998) Subjective experiences of schizophrenic patients treated with antipsychotic medication. Int Clin Psychopharmacol 13: 41–45CrossRefGoogle Scholar
  12. 12.
    Nabulsi AA, Braus AJ, Mack RJ et al. (1996) Reduction of hospital days in sertindole treated patients — one year findings. (Abstract) APA CongressGoogle Scholar
  13. 13.
    Revicki DA (1997) Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 22: 256–266PubMedGoogle Scholar
  14. 14.
    Satterlee W, Dellce M,Beasley C (1996) Effectiveness of olanzapine in long-term continuation treatment. (Abstract) Boca RatonGoogle Scholar
  15. 15.
    Song F (1997) Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials. J Psychopharmacol 11: 65–71PubMedCrossRefGoogle Scholar
  16. 16.
    Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB (1997) Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. Int Clin Psychopharmacol 12: 29–35CrossRefGoogle Scholar
  17. 17.
    Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CJ, Tollefson GD (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407–418PubMedCrossRefGoogle Scholar
  18. 18.
    van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124: 168–175PubMedCrossRefGoogle Scholar
  19. 19.
    Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O (1998) Amisulpride versus flupentixole in schizophrenia with predominantly positive symptomatology—a double-blind controlled study comparing a selective D2-like to a mixed Dl-/D2-like antagonist. The amisulpride study group. Psychopharmacology 137: 223–232PubMedCrossRefGoogle Scholar
  20. 20.
    Wyatt RJ (1994) The cost of schizophrenia-productive person years: making direct and indirect costs understandable. Neuropsychopharmacology 10: 597Google Scholar
  21. 21.
    Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, and the Sertindole Study Group (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–791PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1999

Authors and Affiliations

  • J. Fritze
    • 1
  1. 1.Verband der Privaten KrankenversicherungKölnDeutschland

Personalised recommendations